Inflammation, insulin resistance, and diabetes - Mendelian randomization using CRP haplotypes points upstream

PLoS Medicine

Volumn 5, Issue 8, 2008, Pages 1278-1286

  Brunner, Eric J ^a   Kivimäki, Mika ^a   Witte, Daniel R ^a   Lawlor, Debbie A ^b   Smith, George Davey ^b   Cooper, Jackie A ^a   Miller, Michelle ^c   Lowe, Gordon D O ^d   Rumley, Ann ^d   Casas, Juan P ^e   Shah, Tina ^f   Humphries, Steve E ^a   Hingorani, Aroon D ^a   Marmot, Michael G ^a   Timpson, Nicholas J ^b   Kumari, Meena ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE TOLERANCE TEST; HAPLOTYPE; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; SELF REPORT; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; CAUCASIAN; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; C-REACTIVE PROTEIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS;

EID: 50949134384     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050155     Document Type: Article

References (52)

1. Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenter 132: 2169-2180.
2. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, et al. (2007) Toll-like receptor-4 mediates vascular inflammation and insulin resistance in dietinduced obesity. Circ Res 100: 1589-1596.
3. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
4. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, et al. (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56: 872-878.
5. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, et al. (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes 50: 2384-2389.
6. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596-1600.
7. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM (2003) C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23: 650-655.
8. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53: 693-700.
9. Thoxand B, Lowel H, Schneider A, Kolb H, Meisinger C, et al. (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163: 93-99.
10. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, et al. (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47: 1403-1410.
11. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, et al. (2006) Targeting G-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221.
12. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, et al. (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26: 624-630.
13. Davey Smith G, Ebrahim S (2005) What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? Br Med J 330: 1076-1079.
14. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, et al. (2001) Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 154: 681-689.
15. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, et al. (2005) Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77: 64-77.
16. Hingorani AD, Shah T, Casas JP (2006) Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur Heart J 27: 1261-1263.
17. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, et al. (2006) Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35: 922-931.
18. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, et al. (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366: 1954-1959.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
20. Marmot MG, Davey Smith G, Stansfeld SA, Patel C, North F, et al. (1991) Health inequalities among British Civil Servants: the Whitehall II study. Lancet 337: 1387-1393.
21. Marmot MG, Brunner EJ (2005) Cohort profile: the Whitehall II study. Int J Epidemiol 34: 251-256.
22. Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stansfeld SA, et al. (1997) Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 40: 1341-1349.
23. World Health Organiztion (WHO) (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO.
24. Staiger D, Stock JH (1997) Instrumental variables regression with weak instruments. Econometrica 65: 557-586.
25. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, et al. (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25: 2016-2021.
26. Snijder MB, Dekker JM, Visser M, Stehouwer CD, Yudkin JS, et al. (2003) Prospective relation of C-reactive protein with type 2 diabetes: response to Han et al. Diabetes Care 26: 1656-1657.
27. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, et al. (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 30: 854-860.
28. Kivimaki M, Lawlor DA, Eklund C, Smith GD, Hurme M, et al. (2007) Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol 27: 978-979.
29. Gable DR, Stephens JW, Cooper JA, Miller GJ, Humphries SE (2006) Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men. Diabetes 55: 1504-1511.
30. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
31. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316: 1336-1341.
32. Kivimaki M, Lawlor DA, Davey Smith G, Eklund C, Hurme M, et al. (2007) Variants in the CRP gene as a measure of life-long differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study. Am J Epidemiol 166: 760-764.
33. Zee RY, Ridker PM (2002) Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 162: 217-219.
34. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, et al. (2003) Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 23: 2063-2069.
35. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, et al. (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13: 137-147.
36. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, et al. (2005) A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178: 193-198.
37. Suk HJ, Ridker PM, Cook NR, Zee RY (2005) Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 178: 139-145.
38. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, et al. (2006) Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 113: 1415-1423.
39. Szalai AJ, Alarcon GS, Calvo-Alen J, Toloza SM, McCrory MA, et al. (2005) Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 44: 864-868.
40. Timpson NJ, Smith GD, Ebrahim S (2006) Letter by Timpson et al regarding article, "Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level". Circulation 114: e256.
41. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272.
42. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Tataranni PA, et al. (2003) A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 78: 136-144.
43. Wilier CJ, Bonnycastle LL, Conneely KN, Duren WL, Jackson AU, et al. (2007) Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 56: 256-264.
44. Yudkin JS (2003) Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 27 Suppl 3: S25-S28.
45. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52: 1872-1876.
46. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54: 570-575.
47. Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, et al. (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4: 465-474.
48. Sookoian SC, Gonzalez C, Pirola CJ (2005) Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 13: 2122-2131.
49. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166: 902-908.
50. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, et al. (2006) IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 55: 2915-2921.
51. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49: 517-520.
52. Hamid YH, Urhammer SA, Jensen DP, Glumer C, Borch-Johnsen K, et al. (2004) Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 53: 3342-3345.